Press release from Companies

Published: 2022-11-22 09:42:23

Hamlet Pharma AB: Hamlet Pharma holds a digital investor meeting

Hamlet Pharma is inviting you to a digital investors’ meeting via Zoom, on Wednesday 30th November at 12.00 CET, for dialogue and to follow up from the General meeting. We welcome existing owners, other investors and interested parties to join. The meeting participants will be informed of the company developments and will be invited to ask questions. These may be asked online during the meeting or be sent via e-mail to the addresses listed below. Please use this link to participate: https://lu-se.zoom.us/j/67767519728

  

For more information, contact

Catharina Svanborg, Chairman and founder of Hamlet Pharma, +46-709 42 65 49

Catharina.svanborg@med.lu.se

Martin Erixon, CEO of Hamlet Pharma, +46-733 00 43 77

martin.erixon@hamletpharma.com

About HAMLET Pharma

HAMLET Pharma, listed on Spotlight Stockmarket, develops new drugs for the treatment and prevention of cancer, based on the discovery of the tumoricidal protein-lipid complex, HAMLET. HAMLET has shown therapeutic efficacy in animal models and effects in clinical proof-of-concept studies. The Alpha1H peptide drug candidate, reproduces the effects of HAMLET and has demonstrated therapeutic efficacy in patients with bladder cancer, where cinical trials are ongoing. Bladder cancer is a common and costly form of cancer, with few successful new treatment options. The company is further exploring the use of Alpha1H for other cancer indications, including brain tumors. In addition, Hamlet Pharma develops BAMLET, which is a HAMLET-like complex formed by bovine α-lactalbumin. Data from animal models show promising effects of local BAMLET treatment against colon cancer.

Läs mer hos Cision
Read more about Hamlet Pharma AB

News from Spotlight Group